Published in Pediatrics on March 01, 2010
Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol (2012) 2.32
Infant hearing loss: from diagnosis to therapy Official Report of XXI Conference of Italian Society of Pediatric Otorhinolaryngology. Acta Otorhinolaryngol Ital (2012) 1.57
Yield of screening for long-term complications using the children's oncology group long-term follow-up guidelines. J Clin Oncol (2012) 1.26
Auditory complications in childhood cancer survivors: a report from the childhood cancer survivor study. Pediatr Blood Cancer (2011) 0.98
Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst (2014) 0.94
Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. J Clin Oncol (2014) 0.88
Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report. Biol Blood Marrow Transplant (2016) 0.87
Cisplatin ototoxicity affecting cochlear implant benefit. Otol Neurotol (2011) 0.79
Treatment-induced hearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid tumors: Results from the St. Jude Lifetime Cohort Study. Cancer (2015) 0.79
Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment. Invest New Drugs (2012) 0.77
Cisplatin-induced ototoxicity and the role of pharmacogenetic testing. J Pediatr Pharmacol Ther (2012) 0.77
Cochlear Implantation for Profound Hearing Loss After Multimodal Treatment for Neuroblastoma in Children. Clin Exp Otorhinolaryngol (2015) 0.77
Proton versus conventional radiotherapy for pediatric salivary gland tumors: Acute toxicity and dosimetric characteristics. Radiother Oncol (2015) 0.77
OTOTOXIC EFFECTS OF CARBOPLATIN IN ORGANOTYPIC CULTURES IN CHINCHILLAS AND RATS. J Otol (2012) 0.77
Effective strategy of the combination of high-intensity focused ultrasound and transarterial chemoembolization for improving outcome of unresectable and metastatic hepatoblastoma: a retrospective cohort study. Transl Oncol (2014) 0.76
Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin. Head Neck (2014) 0.75
Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma. Cancer Biol Ther (2016) 0.75
Impact of late radiation effects on cancer survivor children: an integrative review. Einstein (Sao Paulo) (2015) 0.75
DNA Methylation of a Novel PAK4 Locus Influences Ototoxicity Susceptibility following Cisplatin and Radiation Therapy for Pediatric Embryonal Tumors. Neuro Oncol (2017) 0.75
Clinical trials in pediatric neuro-oncology: what is missing and how we can improve. CNS Oncol (2016) 0.75
Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol (2002) 6.68
Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs. Pediatrics (2007) 6.51
Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol (2004) 4.63
Language ability after early detection of permanent childhood hearing impairment. N Engl J Med (2006) 2.99
Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer (2004) 2.73
Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear (1998) 2.61
Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys (2000) 2.33
Estimated prevalence of noise-induced hearing threshold shifts among children 6 to 19 years of age: the Third National Health and Nutrition Examination Survey, 1988-1994, United States. Pediatrics (2001) 2.32
Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer (2009) 2.32
Cochlear implants for children with severe-to-profound hearing loss. N Engl J Med (2007) 2.32
Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles. Mol Biol Cell (2003) 2.30
Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res (2006) 2.28
Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol (2005) 2.23
Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol (2009) 2.17
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res (2004) 2.10
Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther (2007) 2.05
Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer (2006) 1.89
Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol (1989) 1.85
Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys (2002) 1.78
Ototoxicity caused by aminoglycosides. BMJ (2007) 1.67
Current state of knowledge: language and literacy of children with hearing impairment. Ear Hear (2007) 1.65
Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys (2007) 1.62
Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol (1991) 1.56
Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer (2008) 1.55
Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer (2005) 1.53
Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption. Pediatr Blood Cancer (2006) 1.50
Magnesium deficiency and hypertension: correlation between magnesium-deficient diets and microcirculatory changes in situ. Science (1984) 1.47
Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol (2004) 1.46
Hearing loss after radiotherapy for pediatric brain tumors: effect of cochlear dose. Int J Radiat Oncol Biol Phys (2008) 1.46
Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics (2007) 1.42
Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors. J Pediatr Hematol Oncol (2006) 1.41
Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg (1994) 1.38
Ototoxicity. Kidney Int (2007) 1.37
Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs (2007) 1.33
Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol (1996) 1.31
Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors. Int J Radiat Oncol Biol Phys (2004) 1.30
Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol (2006) 1.28
Technology insight: Proton beam radiotherapy for treatment in pediatric brain tumors. Nat Clin Pract Oncol (2004) 1.26
Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer (1998) 1.21
Enhanced cis-platinum ototoxicity in children with brain tumours who have received simultaneous or prior cranial irradiation. Med Pediatr Oncol (1989) 1.21
Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacol Toxicol (1995) 1.17
Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant (1998) 1.13
Rapid word-learning in normal-hearing and hearing-impaired children: effects of age, receptive vocabulary, and high-frequency amplification. Ear Hear (2005) 1.13
Hearing loss in children receiving cisplatin chemotherapy. J Pediatr (1983) 1.09
Ototoxicity induced by gentamicin and furosemide. Ann Pharmacother (2002) 1.08
Ototoxicity of the anticancer drug cisplatin. An experimental study. Acta Otolaryngol (1982) 1.08
Unilateral and mild bilateral hearing loss in children: past and current perspectives. Trends Amplif (2008) 1.06
Hearing assessment in infants and children: recommendations beyond neonatal screening. Pediatrics (2003) 1.04
Round window application of D-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg (2002) 1.04
Cis-dichlorodiammineplatinum (II) (NSC-119875): hearing loss and other toxic effects in rhesus monkeys. Cancer Chemother Rep (1976) 1.03
Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol (2008) 1.01
Delayed effects of ionizing radiation on the ear. Laryngoscope (1985) 0.99
Assessment of school functioning among Israeli Arab children with hearing loss in the primary grades. Am Ann Deaf (2006) 0.99
A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer (2008) 0.98
Facilitating care for childhood cancer survivors: integrating children's oncology group long-term follow-up guidelines and health links in clinical practice. J Pediatr Oncol Nurs (2004) 0.97
Cisplatin ototoxicity and otoprotection with sodium salicylate. Eur Arch Otorhinolaryngol (2006) 0.96
Cochlear implantation in the very young child: Long-term safety and efficacy. Laryngoscope (2009) 0.96
Health-related quality of life in survivors of Wilms' tumor and advanced neuroblastoma: aA cross-sectional study. J Clin Oncol (2000) 0.94
Vitamin E reduces cisplatin ototoxicity. Laryngoscope (2004) 0.93
Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system. Bone Marrow Transplant (2006) 0.92
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr Hematol Oncol (2007) 0.91
The NCCN Guideline Program: a conceptual framework. Oncology (Williston Park) (1997) 0.90
Cisplatin ototoxicity: the importance of baseline audiometry. Am J Clin Oncol (1999) 0.89
Radiation effects on the inner ear. Arch Otolaryngol (1968) 0.89
Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour. Eur J Cancer (2008) 0.89
Antioxidant protection in a new animal model of cisplatin-induced ototoxicity. Hear Res (2004) 0.89
cis-platinum ototoxicity in children. Laryngoscope (1991) 0.87
Assessment of hearing in very young children receiving carboplatin for retinoblastoma. Eur J Cancer (2006) 0.87
The mutual independence of the endolymphatic potential and the concentrations of sodium and potassium in endolymph. J Clin Invest (1973) 0.86
Carboplatin in pediatric malignancies. Semin Oncol (1994) 0.85
Ototoxicity following pediatric hematopoietic stem cell transplantation: a prospective cohort study. Pediatr Blood Cancer (2004) 0.85
Pediatric sensorineural hearing loss after temporal bone radiation. Am J Otol (1995) 0.84
Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol. Med Pediatr Oncol (1996) 0.84
X-ray irradiation of the inner ear of the guinea pig. Early degenerative changes in the cochlea. Acta Otolaryngol (1970) 0.84
Cisplatin therapy in infants: short and long-term morbidity. Br J Cancer Suppl (1992) 0.83
Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: results of the SFOP NBL90 study. Pediatr Blood Cancer (2005) 0.81
Hearing loss in early infancy affects maturation of the auditory pathway. Dev Med Child Neurol (2002) 0.81
Hearing loss in children. Pediatr Rev (2009) 0.81
Cochlear implantation following treatment for medulloblastoma. Laryngoscope (2010) 0.80
Radiotherapy enhanced ototoxicity of cisplatin in children. Acta Otolaryngol Suppl (1997) 0.79
Effects of X-ray irradiation on hearing in guinea pigs. Acta Otolaryngol (1985) 0.79
Enhanced cis-platinum neurotoxicity in pediatric patients with brain tumors. J Neurooncol (1983) 0.79
Dependence of noise-induced hearing loss upon perilymph magnesium concentration. J Acoust Soc Am (1983) 0.79
Early morphological and chemical changes induced by cisplatin in the guinea pig organ of Corti. J Laryngol Otol (1986) 0.78
[Platinum derivatives in pediatric oncology]. Arch Fr Pediatr (1993) 0.76
Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature (2010) 3.70
Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol (2005) 2.28
Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol (2002) 1.82
Carboplatin ototoxicity in retinoblastoma: onset and monitoring. Pediatr Blood Cancer (2009) 1.42
Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol (2005) 1.39
Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer (2008) 1.11
Clear cell ependymoma: a clinicopathologic and radiographic analysis of 10 patients. Cancer (2003) 1.06
Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer (2007) 1.05
Liability issues for data monitoring committee members. Clin Trials (2004) 1.05
Natural history of thyroid nodules in survivors of pediatric Hodgkin lymphoma. Pediatr Blood Cancer (2006) 0.87
Differential item functioning in quality of life measure between children with and without special health-care needs. Value Health (2011) 0.86
Late effects on the urinary bladder in patients treated for cancer in childhood: a report from the Children's Oncology Group. Pediatr Blood Cancer (2009) 0.84
Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). J Neurooncol (2012) 0.83
The use of bone age for bone mineral density interpretation in a cohort of pediatric brain tumor patients. Pediatr Radiol (2008) 0.79
Dysembryoplastic neuroepithelial tumors and cognitive outcome: cure at a price? Cancer (2010) 0.77